Stella Diagnostics (Stella Diagnostics) Purchase Of Business : $ Mil (TTM As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Stella Diagnostics Purchase Of Business?

Stella Diagnostics's purchase of business for the three months ended in Sep. 2023 was $0.00 Mil. It means Stella Diagnostics spent $0.00 Mil on purchasing business.

Compared with last quarter ($0.00 Mil in Sep. 2022 ), Stella Diagnostics spent the same money on purchasing business in Sep. 2023 ($0.00 Mil).

Stella Diagnostics Purchase Of Business Historical Data

The historical data trend for Stella Diagnostics's Purchase Of Business can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stella Diagnostics Purchase Of Business Chart

Stella Diagnostics Annual Data

Trend

Purchase Of Business

Stella Diagnostics Quarterly Data
	Sep22	Sep23
Purchase Of Business	-	-

Stella Diagnostics Purchase Of Business Calculation

The amount used to purchase business.

Stella Diagnostics Purchase Of Business Related Terms

Thank you for viewing the detailed overview of Stella Diagnostics's Purchase Of Business provided by GuruFocus.com. Please click on the following links to see related term pages.

Stella Diagnostics (Stella Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Stella Diagnostics Inc (OTCPK:SLDX) » Definitions » Purchase Of Business

Comparable Companies

Traded in Other Exchanges

N/A

Address

50 West Broadway, Suite 300, Salt Lake City, UT, USA, 84104

Website

https://www.stelladx.com

Stella Diagnostics Inc is a molecular diagnostics-based organization focused on improving patient management strategies for people living with severe esophageal disease. It is developing first-line diagnostic tools that provide superior molecular information for providers as compared to the current standard screening protocols.